Immunogen (IMGN) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results
July 31, 2020 6:30 AM EDTEncouraging Data from FORWARD II Study of Mirvetuximab in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO
Preclinical Data on Next Generation Anti-FR ADC, IMGN151, Demonstrating Enhanced Anti-Tumor Activity, Presented at AACR
Positive Opinion on Orphan Drug Designation for IMGN632 for Treatment of BPDCN Adopted by EMAs COMP
IND Application for Novel ADAM9-Targeting ADC, IMGC936, Accepted by FDA
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS... More
